Ironwood Pharmaceuticals, Inc. IRWD
4.13
(0.06)
(1.43%)
as of 25 Sep
- Market cap
- $692.4M
- P/E
- 5.2×
Follow IRWD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(9.92%) | (8.53%) | (37.07%) | (55.26%) | |
| 7.27% | 6.42% | 26.83% | 41.35% | ||
ROIC |
42.79% | 57.33% | 84.97% | 101.61% | |
Return on Tangible Assets |
81.55% | 67.91% | 103.05% | 76.73% | |
Average Days of Receivables |
129.61 | 57.61 | 106.86 | 105.69 | |
Free Cash Flow per Share |
0.42 | 0.78 | 0.69 | 1.13 | |
Free Cash Flow |
67.65 | 127.01 | 112.21 | 185.56 | |
Capital Expenditures |
(0.03) | (0.03) | — | — | |
Piotroski F-Score |
6.00 | 5.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
14.69% | 23.60% | 19.08% | 61.38% | |
Accounts Receivable Turnover |
3.45 | 4.60 | 4.97 | 3.91 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.69) | (0.66) | (0.40) | (0.37) | |
Research and Development Expense of Revenue |
29.11% | 32.12% | 24.80% | 22.78% | |
Selling, General and Administrative Expense of Revenue |
28.48% | 27.78% | 19.37% | 16.58% | |
Share Based Compensation of Revenue |
5.31% | 5.82% | 4.32% | 3.68% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.37 | 5.29 | 1.10 | 1.43 | |
Depreciation/Fixed assets |
0.52 | 0.55 | 0.58 | 0.63 | |
Capex/Depreciation |
(0.02) | (0.02) | 0.00 | 0.00 | |
Revenue per Share |
2.09 | 1.83 | 2.21 | 2.37 | |
Operating CF per Share |
0.42 | 0.79 | 0.69 | 1.13 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
8.42% | 8.11% | 28.26% | 33.36% |
Columns are period end dates